An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions.
antibody engineering
antibody–cytokine fusion proteins
fibroblast activation protein
interleukin-2
tumor necrosis factor
Journal
Antibodies (Basel, Switzerland)
ISSN: 2073-4468
Titre abrégé: Antibodies (Basel)
Pays: Switzerland
ID NLM: 101587489
Informations de publication
Date de publication:
14 Apr 2023
14 Apr 2023
Historique:
received:
10
02
2023
revised:
28
02
2023
accepted:
04
04
2023
medline:
24
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
The delivery of specific cytokine payloads to a neoplastic environment employing antibodies able to selectively accumulate at the tumor site represents an attractive strategy to stimulate an immune response to cancer. Whilst conventional antibody-cytokine fusions based on a single payload have shown potent anticancer activity, the concomitant delivery of two cytokine payloads may further improve the therapeutic outcome as the immune system typically adopts multiple signals to reinforce an antitumor strategy. We here describe a potency-matched dual-cytokine antibody fusion protein containing a tumor-targeting antibody fragment specific to human fibroblast activation protein (FAP), simultaneously linked to both interleukin-2 (IL2) and a tumor necrosis factor (TNF) mutant. The resulting fusion protein, termed IL2-7NP2-TNF
Identifiants
pubmed: 37092450
pii: antib12020029
doi: 10.3390/antib12020029
pmc: PMC10123652
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Immunother Cancer. 2014 Sep 16;2(1):26
pubmed: 31546315
Br J Cancer. 1987 Mar;55(3):287-90
pubmed: 3105570
Br J Cancer. 2013 Sep 3;109(5):1206-13
pubmed: 23887603
Cancer Immunol Res. 2019 Mar;7(3):348-354
pubmed: 30824549
Cell Mol Life Sci. 2022 Sep 6;79(10):509
pubmed: 36066630
Cell Mol Immunol. 2022 Feb;19(2):192-209
pubmed: 35043005
Mol Cancer Ther. 2019 Sep;18(9):1544-1554
pubmed: 31213507
J Immunother. 2006 Sep-Oct;29(5):477-88
pubmed: 16971804
J Immunol. 2014 Jun 15;192(12):5451-8
pubmed: 24907378
Cancer Res. 2003 Jun 15;63(12):3202-10
pubmed: 12810649
J Clin Oncol. 1999 Jul;17(7):2105-16
pubmed: 10561265
Adv Drug Deliv Rev. 2019 Feb 15;141:67-91
pubmed: 30201522
Int J Cancer. 2020 May 1;146(9):2518-2530
pubmed: 31374124
PLoS One. 2012;7(9):e44482
pubmed: 23028547
Int J Cancer. 2010 Jul 1;127(1):101-10
pubmed: 19877124
Biochem Insights. 2008 Jul 22;2008:15-21
pubmed: 24115841
Exp Mol Pathol. 2013 Dec;95(3):350-56
pubmed: 24422232
Oncogene. 2018 Aug;37(32):4343-4357
pubmed: 29720723
J Nucl Med. 2018 Sep;59(9):1423-1429
pubmed: 29626120
Blood. 2003 Dec 15;102(13):4384-92
pubmed: 12933583
Cancer. 1994 Feb 1;73(3 Suppl):824-31
pubmed: 8306266
J Invest Dermatol. 2013 Mar;133(3):751-758
pubmed: 23096716
J Clin Oncol. 1995 Mar;13(3):688-96
pubmed: 7884429
Radiology. 2021 Feb;298(2):393-402
pubmed: 33258746
J Invest Dermatol. 2003 Feb;120(2):182-8
pubmed: 12542520
Cancer Immunol Immunother. 2015 Aug;64(8):999-1009
pubmed: 25971540
Cancer Immunol Immunother. 2018 Sep;67(9):1381-1391
pubmed: 29971465
Clin Exp Med. 2020 Feb;20(1):121-130
pubmed: 31745677
Int J Cancer. 1993 Mar 12;53(5):829-36
pubmed: 8449608
Cancer Immunol Immunother. 2002 Oct;51(8):449-60
pubmed: 12202906
Mol Med Rep. 2018 Feb;17(2):2593-2599
pubmed: 29207091
Int J Cancer. 1994 Jun 1;57(5):656-63
pubmed: 8194873
Clin Pharmacol. 2013 Aug 20;5:29-45
pubmed: 23990735
Proteomics Clin Appl. 2014 Jun;8(5-6):454-63
pubmed: 24470260
Eur Endocrinol. 2016 Mar;12(1):12-17
pubmed: 29632581
J Nucl Med. 2021 Jun 1;62(6):779-786
pubmed: 33097632
J Nucl Med. 2019 Oct;60(10):1421-1429
pubmed: 30850501
Int J Cancer. 2008 Jun 1;122(11):2405-13
pubmed: 18271006
Mol Cancer Ther. 2006 Apr;5(4):1029-40
pubmed: 16648575
Protein Eng Des Sel. 2018 May 1;31(5):173-179
pubmed: 29982719
Mol Cancer Ther. 2014 Jan;13(1):112-21
pubmed: 24198185
Front Oncol. 2019 Nov 13;9:1228
pubmed: 31799191
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1604-1617
pubmed: 33179149
Front Biosci (Landmark Ed). 2018 Jun 1;23(10):1933-1968
pubmed: 29772538
BMC Cell Biol. 2014 May 21;15:16
pubmed: 24885257
Proc Natl Acad Sci U S A. 2021 Apr 20;118(16):
pubmed: 33850024
Drug Discov Today. 2016 Jan;21(1):180-189
pubmed: 26526566
Mol Cancer Ther. 2017 Nov;16(11):2442-2451
pubmed: 28716814
Oncologist. 2018 Oct;23(10):1133-e112
pubmed: 30076277
Cancer Res. 1988 Apr 15;48(8):2179-83
pubmed: 3349488
Antibodies (Basel). 2021 Mar 09;10(1):
pubmed: 33803078
J Immunother Cancer. 2022 Sep;10(9):
pubmed: 36104101
J Interferon Cytokine Res. 2019 Jan;39(1):6-21
pubmed: 29889594